NULISA CNS Disease Biomarker Platform
Time: 8:30 am
day: Conference Day Two
Details:
• The only high-plex, high sensitivity platform for investigation of biomarkers of neurodegenerative diseases and treatment response
• NULISA™ combines ultra-sensitive femtogram level detection with barcode-based highplex biomarker analysis
• The NULISA CNS Disease Panel is unique in enabling investigation of hundreds of proteins involved in neuroinflammation, vascular, and synaptic dysfunction, and proteinopathies
• NULISA offers the unique ability to translate multiplexed biomarker profiling for discoveries to single and low-plex biomarker assays run with the same assay on the same instrument
• NULISA single-, low-, and high-plex assays all run fully automated on the ARGO HT System
• NULISA CNS Disease Panel 120 and Inflammation Panel 250 are used for exploratory clinical research into therapeutic effects on neurodegenerative disease processes
• NULISA IVD and ARGO DX in development with funding from Gates Ventures and DxA
